Can a Dopamine Transporter Gene Change How Amphetamine Feels? Evidence From 152 Volunteers

Short answer: In a controlled experiment involving 152 independent healthy adults, one dopamine transporter gene marker, SLC6A3 rs460000, was associated with differences in self-reported stimulation and euphoria after oral d-amphetamine. The reported genotype-by-dose interactions were nominally significant (stimulation p = .015; euphoria p = .025), but the investigators did not establish a consistent three-genotype dose trend or significant genotype differences in their Digit Symbol Substitution Test, blood-pressure, or heart-rate responses. Multiple testing limits confidence in the exploratory genetic result. A blood specimen was obtained for DNA analysis, not chemical quantification of amphetamine. This study therefore cannot establish a particular person’s venous whole-blood drug concentration, last use, intoxication, ability to drive, or responsibility for an incident.

The underlying experiment was reported by Hamidovic, Dlugos, Palmer, and de Wit in Behavior Genetics (2010), Polymorphisms in Dopamine Transporter (SLC6A3) are Associated with Stimulant Effects of d-Amphetamine: An Exploratory Pharmacogenetic Study Using Healthy Volunteers. The original primary study and DOI identify the exact research discussed here. Its reported treatment, genotyping, questionnaires, physical observations, significant results, and nonsignificant results must remain separate when interpreting the evidence.

What scientific question did the investigators actually test?

The investigators asked whether naturally occurring variation in the gene encoding the dopamine transporter was associated with differences in responses to the same experimentally administered amphetamine conditions. The gene is commonly called SLC6A3 or DAT1. Four individual sequence variants, or single-nucleotide polymorphisms (SNPs), were assessed. The hypothesis was mechanistically plausible because amphetamine changes dopamine signaling partly through its actions at the transporter. Plausibility, however, is different from experimentally demonstrating that a particular genetic base substitution caused an observed psychological response.

Importantly, the study was neither a trial of treatment efficacy in diagnosed attention-deficit/hyperactivity disorder nor an examination of illicit methamphetamine use. It recruited healthy screened volunteers, observed them for several hours after specified oral doses of d-amphetamine, and analyzed the relationship between inherited markers and measured or reported responses. The narrow result is a group-level exploratory pharmacogenetic association. It is not a method that retrospectively determines how a different person behaved after a disputed drug exposure.

How many independent humans participated?

152 individuals, consisting of 85 men and 67 women, contributed to the principal dataset. The reported mean age was 22.8 years, with a standard deviation of 3.4 years. Eligibility was restricted to healthy, ancestry-screened Caucasian adults aged 18–35. The investigators used psychiatric and medical screening and restricted higher nicotine and caffeine use. Women were scheduled during the follicular phase of the menstrual cycle, a deliberate attempt to limit one potential source of variation in drug response.

Each person participated in three relevant study sessions. Those repeated visits do not make 456 independent biological subjects. Multiple questionnaire ratings taken from the same individual at different minutes are also repeated observations, not additional recruits. Likewise, four genotyped positions in one person’s DNA do not create four biological participants. Maintaining the correct denominator matters when evaluating precision, rare genotype categories, and whether an exploratory finding can be applied outside this relatively young and selected sample.

What drug was given, by which route, and at what doses?

At separate, double-blind visits, participants swallowed capsules containing 10 mg oral d-amphetamine, 20 mg oral d-amphetamine, or dextrose-only placebo, in randomized order. The experimental sessions were separated by at least 48 hours. The report mentions an additional 5-mg visit for a subset, but those observations were excluded from the three-condition analyses discussed here. Consequently, no result should be invented for that excluded dose.

The administered substance was d-amphetamine; it was not methamphetamine, lisdexamfetamine, a mixed amphetamine-salt product, or racemic amphetamine. Nor was the placebo an active stimulant or a sedative. Administration was oral, not intravenous, intranasal, smoked, or transdermal. Capsule milligrams identify an assigned dose, not the mass of unchanged parent compound subsequently present in someone’s blood. Without direct quantitative toxicology, the study does not provide a measured relationship between that dose and forensic whole-blood drug levels.

How did the visit schedule affect interpretation?

Sessions generally ran from 9:00 a.m. to 1:00 p.m. Baseline mood, heart rate, and blood pressure were recorded; the assigned capsule was taken at approximately 9:30 a.m. Subjective ratings and physiological measures were obtained at approximately 30, 60, 90, 150, and 180 minutes after ingestion. The paper describes the cognitive task once, at about 120 minutes following the capsule. Thus the cognitive score was not a continuous measurement and was not a timed series comparable to a plasma pharmacokinetic profile.

Participants were instructed to avoid recreational drugs, alcohol, nicotine, and caffeine before each visit, and screening samples were collected to assess compliance. These controls made the administered-dose contrast more interpretable in this laboratory population. They did not simulate the sleep loss, mixed substances, comorbid illness, distraction, or unpredictable circumstances of an actual impaired-driving or medical-forensic investigation. The session clock describes what the investigators did, not a validated method for dating an unknown exposure in somebody else.

Which responses were psychological questionnaires?

The primary subjective instrument was the Addiction Research Center Inventory (ARCI), a 49-item questionnaire. Its reported domains included stimulation, euphoria, intellectual efficacy and energy, sedation, and dysphoria. A participant’s answer expresses a self-perceived state. It cannot be directly equated with objectively measured speed, accuracy, dangerousness, safe driving, or molecular drug concentration. The authors focused especially on stimulation, euphoria, and intellectual efficacy and energy because those are common subjective effects of stimulant administration.

The investigators reduced repeated responses to a trapezoidal area under the curve for each questionnaire scale. This AUC is an integrated mood-rating-over-time score. It is not a concentration-versus-time pharmacokinetic AUC of chemically measured amphetamine in venous whole blood, plasma, or serum. Treating the two as if they had equivalent physical meaning would improperly transform a survey endpoint into toxicological evidence. Here an AUC value has no ng/mL unit and no demonstrated conversion factor to one.

What objective performance and physiological outcomes were recorded?

At roughly two hours after dosing, participants completed the Digit Symbol Substitution Test (DSST). The task asks a participant to pair numbers with symbols during a 90-second interval and counts correct substitutions. It captures elements of visual scanning, psychomotor speed, attention, and task familiarity. A higher number correct need not imply adequate hazard recognition, multitasking, judgment, response inhibition under roadway conditions, or the absence of all drug effects. The DSST was one laboratory performance outcome, not an on-road validation study.

Heart rate and blood pressure were obtained with a physiological monitor at repeated intervals. Their drug-related changes help establish that the capsule produced detectable average physiological effects. But cardiovascular response is not interchangeable with a person’s dose absorbed, parent-drug concentration, or functional impairment. The critical distinction in this publication is between an overall drug effect across participants and a difference in that drug effect between genetic groups. The former occurred across several measures; the latter was not established for the objective DSST and cardiovascular outcomes.

What genetic material and genotyping method were used?

Volunteers provided a blood sample for DNA extraction. The investigators genotyped four SLC6A3 SNPs: rs3756450, rs460000, rs37022, and rs6869645. They used an Illumina GoldenGate-based genotyping array with imaging and genotype-calling procedures. A separate panel of ancestry-informative markers was examined to evaluate whether self-reported ancestry broadly matched genetic structure. The authors reported duplicate-sample genotype concordance consistent with an estimated error rate below 1%.

None of these procedures chemically measured the administered d-amphetamine. A DNA genotype is a sequence result, not a parent-drug or metabolite result. This distinction applies even when both testing processes might use blood drawn from a vein. The research did not provide a quantified parent amphetamine measurement in a legally collected venous whole-blood toxicology sample, or validated separate plasma or serum concentrations. No LC–MS/MS or GC–MS drug result, detection limit, quantitation limit, or individual concentration-to-effect conversion was reported.

What were the rs460000 genotype-group sizes?

For rs460000, 83 people had C/C, 61 had A/C, and 8 had A/A. Because the rare A/A subgroup was small, the investigators combined A/A with A/C, producing a comparison of 83 C/C versus 69 people carrying at least one A allele. The combined-group contrast therefore answers a particular dominant-model hypothesis. It cannot establish that the A/A homozygotes respond in a linearly ordered way compared with A/C, and their individual subgroup estimate would be especially imprecise with only eight people.

The same pooling approach applied to the other SNPs because rare homozygous categories were too small for well-powered recessive analyses. That makes the experiment more practical but means genetic dose-response across all three genotypes was not robustly characterized. The number of genotyped individuals is fixed at 152. It should not be inflated by counting 304 alleles as 304 separate people.

Did amphetamine cause measurable average changes independent of genotype?

Yes, within this randomized crossover protocol, active treatment versus placebo produced strong overall dose-related differences across multiple reported responses. For example, the drug main effect was significant for ARCI stimulation, F(2,302) = 58.7, p ≤ .001; for euphoria, F(2,302) = 50.4, p ≤ .001; and for intellectual efficacy and energy, F(2,302) = 39.1, p ≤ .001. The sedation rating decreased under the drug, and dysphoria scores also changed significantly. These are group-level questionnaire analyses, not proof of a uniform experience in everyone.

The authors also reported significant general drug effects for DSST correct substitutions, F(2,284) = 12.13, p ≤ .001, systolic blood pressure, F(2,302) = 110.92, p ≤ .001, diastolic blood pressure, F(2,300) = 59.46, p ≤ .001, and heart rate, F(2,302) = 26.667, p ≤ .001. These confirm that the study detected several average effects of orally administered d-amphetamine under its laboratory conditions. They do not establish an rs460000-specific improvement on those same objective outcomes.

Which rs460000 findings were nominally statistically significant?

The pooled C/C-versus-A-carrier analysis produced a reported genotype-by-dose interaction for subjective stimulation, F(2,300) = 4.42, p = .015. It also produced a genotype-by-dose interaction for subjective euphoria, F(2,300) = 3.72, p = .025. The C/C group reported approximately twice as much stimulation and euphoria as the combined A-carrier group after the active doses, according to the authors’ description of the group means. The groups were reported to be similar under placebo.

That observed difference is scientifically more limited than a genetic law. It describes average self-reports in 83 versus 69 volunteers, obtained under a particular measurement schedule and analytical pooling decision. The authors chose an exploratory conventional significance criterion rather than familywise correction over every studied SNP and endpoint. An apparent twofold ratio of questionnaire response is not a twofold ratio of physically assayed amphetamine, receptor occupancy, intoxication, risk of violence, or driving impairment.

What did tests of all three rs460000 genotypes show?

A particularly important qualification is that analyzing C/C, A/C, and A/A as three distinct classes did not establish the same significant effect. The stimulation analysis returned F(4,298) = 2.12, p = .080, and the euphoria analysis returned F(4,298) = 1.89, p = .113. Both are genuine nonsignificant tests under the paper’s stated conventional level. The investigators also observed no orderly additive response pattern in which every A/A volunteer group mean fell below the A/C group.

This discrepancy does not automatically invalidate the pooled contrast; the rare A/A group contained only eight participants, making three-category estimation less powerful. But it prevents claiming a validated number-of-A-alleles dose rule. Nor can it justify predicting how one particular C/C or A/A person would feel. A statistically nonsignificant result does not prove perfect equality, and a nominally significant pooled comparison does not prove deterministic biology.

Did any of the three other dopamine-transporter variants show the same drug-response pattern?

The original authors reported no significant genotype-by-drug interactions across the ARCI domains for the other tested SLC6A3 variants—rs3756450, rs37022, and rs6869645. The article does not supply a complete exact p-value for every one of those individual interactions; none should be fabricated. It did note a modest baseline stimulation-rating difference for rs3756450 before drug administration: T/T participants averaged 2.02 ± 1.03 versus 2.53 ± 1.00 in the combined C-allele-carrier group, with p = .013. That is a baseline questionnaire contrast, not proof of genotype-specific response to the administered amphetamine.

For rs6869645, the groups differed in sex distribution: 14 men and four women among C/T carriers, versus 71 men and 63 women among C/C. The authors therefore included sex in relevant analyses. Selective population structure checks and covariate adjustment help interpretation, but do not independently validate effects in other ancestry groups or clinical populations. The conclusion must remain limited to the particular measured SNPs and sample.

Did genotype predict cognitive performance or cardiovascular response?

No statistically significant genotype-specific modification of the drug response on DSST number correct, heart rate, or systolic or diastolic blood pressure was reported for the variants studied. The paper provided significant general drug main effects for these endpoints, but that is a different question. For example, DSST performance changed after d-amphetamine across the study population; the finding does not establish that rs460000 C/C participants obtained a uniquely greater DSST benefit than carriers of an A allele. Likewise, higher average cardiovascular values following the active capsule were not shown to discriminate the genetic groups on drug response.

This is an important forensic constraint. The positive genetic result came from subjective stimulation/euphoria, not an objective driving simulator, an observed hazardous task, a chemical concentration assay, or a validated impairment classification. It would be wrong to use a person’s rs460000 result to infer that a favorable or unfavorable driving test outcome was inevitable. The source offers no sensitivity, specificity, or positive predictive value for such an application.

How did multiple-comparison testing limit the genetic conclusion?

Four genetic markers, multiple psychological scales, several dose conditions, and physiological and performance outcomes generate many possible statistical comparisons. The authors candidly described their experiment as exploratory and generally used a two-sided p < .05 threshold, without applying a comprehensive correction to all tests. The source discussed a hypothetical more restrictive Bonferroni level of approximately .0014. Its genotype-by-drug interaction p-values of .015 and .025 are plainly above that number.

The authors also described specific stimulation contrasts as potentially persisting after stricter adjustment while euphoria findings would not. However, the published figure uses symbols giving only upper bounds, not the exact p-value for every active-dose pairwise contrast, and the text does not resolve all multiplicity questions. That technical ambiguity warrants restraint, not a fabricated exact adjusted p-value. The most defensible presentation is that the reported pooled rs460000 results are nominal exploratory associations, with uncertain familywise robustness and a nonsignificant full three-genotype analysis.

What do the original numerical tests support—and what do they not support?

The paper supports an experimentally elicited average response to oral d-amphetamine, alongside a provisional relationship between rs460000 grouping and particular subjective sensations. It does not support a universal genetic test for dose sensitivity or an equivalence between questionnaire effect size and toxicological exposure. The original tests are laid out below so that the positive and nonsignificant findings cannot silently be blended.

Why does rs460000 not identify a person’s amount of amphetamine?

Gene sequence does not reveal how much active parent drug passed into the bloodstream after swallowing a capsule. Actual systemic concentration depends on factors not quantitatively resolved here, including formulation, absorption, distribution, elimination, interactions, physiology, and timing. More fundamentally, the investigators did not take the sequence of forensic toxicology measurements needed to calibrate one of these DNA results to a specific concentration. The rs460000 categories are inherited states, not chemical analytes and not clock readings.

The trial gave known 10- and 20-mg nominal doses, making the randomized drug-versus-placebo comparison meaningful. It did not report post-dose d-amphetamine in a legally collected human venous whole-blood assay or in separated plasma or serum. It did not measure parent amphetamine or metabolites in quantitative urine, oral-fluid, sweat, hair, vitreous, breath, or milk samples. There were no chromatographic amphetamine concentration curves, validated matrix-specific detection or quantitation limits, or an enantiomer-specific forensic drug method within the reported results. Assigning a blood level from the questionnaire or SNP would invent a laboratory measurement.

Why are the blood specimen and the screening samples not chemical proof of exposure level?

The blood specimen in this study was used for DNA genotyping. A biological specimen can support very different scientific questions depending on its handling and assay: DNA sequence, blood-cell count, serum chemistry, and quantified parent drug are not interchangeable results. A researcher could collect venous blood for one purpose without producing any interpretable whole-blood amphetamine concentration at all. Indeed, that is the relevant distinction here.

Urine and breath samples collected before each dosing session were compliance screens. They did not measure the administered drug’s time-varying concentration after the capsule or quantify an individual’s whole-blood exposure. Nor can a prestudy breath-alcohol screen establish the person’s earlier drinking history or translate into an amphetamine toxicology result. For a general explanation of why the physically collected matrix determines the analytical conclusion, see the site’s actually published guides to biological matrices and confirmatory drug testing.

What can the study say about ADHD or substance-use vulnerability?

The study selected particular variants partly because other research had discussed dopamine-transporter biology in relation to ADHD and substance-use phenotypes. That scientific motivation did not make the experiment a diagnostic study of ADHD. Participants were selected as psychiatrically healthy. The authors did not directly test whether rs460000 prospectively predicts an ADHD diagnosis, stimulant treatment success in ADHD patients, development of stimulant-use disorder, or subsequent behavior in a legally disputed setting. The documented drug response was a short-term sensation after administered d-amphetamine, not a verified clinical disease endpoint.

Likewise, the paper does not establish the molecular function of rs460000. A variant may be associated with or inherited alongside another functional sequence region, and an observational genotype contrast does not pinpoint the biochemical mediator. A plausible link to dopamine transport is not equivalent to directly measuring extracellular dopamine or brain transport activity during the experiment. Any application to a new person, ethnicity, age group, medication regimen, or clinical diagnosis would need new validation.

How should these findings be used when evaluating forensic or medical claims?

Start with the disputed proposition. If it concerns which drug was present or its concentration, request the actual collection, specimen, analytes, confirmation method, calibration, quality controls, and reportable results. If it concerns what the person felt, a questionnaire result obtained under controlled laboratory conditions may inform a scientific discussion, but it does not establish the person’s own feelings without contemporaneous evidence. If it concerns driving, judgment, injury, witness perception, or intent, appropriate independent functional or case-specific evidence is required.

Keeping these evidentiary categories separate prevents a scientific result from silently migrating across causal steps. This study provides a valid reason to investigate biological variation in subjective stimulant response. It does not establish that a particular C/C carrier had more amphetamine in blood, was more impaired, remembered an event less accurately, drove unsafely, committed an act, or caused an injury. Neither positive research p-values nor nonsignificant outcomes settle any such personalized legal conclusion. The strongest evidence-based use of the paper is explanatory and hypothesis-generating rather than person-classifying.

Frequently asked scientific questions

1. Did the study investigate methamphetamine or lisdexamfetamine?

No. The active drug was oral d-amphetamine at 10 mg and 20 mg, compared with a dextrose placebo. The paper cannot be relabeled as a controlled methamphetamine, mixed-salts, or lisdexamfetamine experiment.

2. Were there 152 people or 456 independent participants?

There were 152 independent people. Each attended three relevant randomized crossover visits; repeated visits improve within-person comparisons but do not create additional biological participants or independent genotypes.

3. Did rs460000 predict everyone’s objective cognitive test score?

No. The study reported significant overall drug effects on DSST correct substitutions but no statistically significant genotype-specific modification of drug response on the DSST. The positive rs460000 comparison concerned subjective stimulation and euphoria ratings.

4. Were all rs460000 genotype analyses statistically significant?

No. The pooled C/C-versus-A-carrier analyses yielded nominal interaction p = .015 and .025, whereas the three-category tests were nonsignificant for stimulation (p = .080) and euphoria (p = .113). Multiple testing further limits an individualized genetic inference.

5. Did a blood draw establish measured d-amphetamine concentration?

No. Blood was used to extract DNA for genotyping. The report included no quantitative postdose parent d-amphetamine assay in human legal venous whole blood or separated plasma or serum. A gene test is not a blood drug test.

6. Can subjective euphoria AUC be converted into an amphetamine ng/mL value?

No. The reported ARCI AUC integrates subjective questionnaire scores across time. It is not pharmacokinetic drug concentration AUC, has no validated conversion to ng/mL, and cannot reveal the person’s precise absorption or elimination course.

7. Can rs460000 establish last use, driver impairment, witness accuracy, or a case cause?

No. The experiment did not measure an individual legal drug-use time estimator, driving performance, eyewitness accuracy, road safety, or specific injury or incident causation. Group-level exploratory genetics cannot substitute for independent case-specific analytical and behavioral evidence.

Primary reference and methodological context

Hamidovic A, Dlugos A, Palmer AA, de Wit H. Polymorphisms in Dopamine Transporter (SLC6A3) are Associated with Stimulant Effects of d-Amphetamine: An Exploratory Pharmacogenetic Study Using Healthy Volunteers. Behavior Genetics. 2010;40(2):255–261. Original peer-reviewed empirical DOI: 10.1007/s10519-009-9331-7. Forensic interpretation of any separate case would still depend on the actual legally collected specimen, analytes, validated analytical method, findings, and incident-specific evidence—not the genetic marker alone.